Loading patent…
OwnerNorman Wong, Joseph Tucker +1inventors
InventorsNorman Wong, Joseph Tucker, David McCaffrey
Estimating the term…
Compounds and methods are provided for treating patients suffering from health condition associated with an expression state of a gene such as fertility disorders, cancer, proliferative diseases, vascular diseases, wounds requiring therapeutic intervention, inflammation, and pulmonary disorders by administering to said patient a compound capable of modulating egr-1 and/or an egr-1 response element consensus sequence thereby altering the expression state of said gene. Also described are new methods for screening compounds to identify effectors of egr-1 and/or egr-1 consensus sequence elements and methods for treating patients by administering such effectors to modulate egr-1 and/or egr-1 consensus sequences to thereby modify expression of genes associated therewith to in turn treat diseases or other physiological conditions associated with such gene expression.
The use of a compound capable of modulating transcription arising from an egr-1 response element consensus sequence and expression state of a gene in manufacture of a medicament for the treatment of a disease or health condition associated with an expression state of a gene associated with an egr-1 response element consensus sequence.
The use of claim wherein said disease is selected from the group consisting of cancer and other proliferative diseases.
The use of a compound capable of modulating transcription arising from an egr-1 response element consensus sequence and expression state of p21 in manufacture of a medicament for the treatment of a disease or health condition selected from the group consisting of cancer, other proliferative diseases, and susceptibility to cellular transformation.
The use of a compound capable of modulating transcription arising from an egr-1 response element consensus sequence and expression state of p53 in manufacture of a medicament for the treatment of a health condition requiring treatment selected from the group consisting of induced cell cycle arrest, cell injury and need for cell repair.
The use of a compound capable of modulating transcription arising from an egr-1 response element consensus sequence and expression state of FGF-2 in manufacture of a medicament for the treatment of a health condition requiring treatment selected from the group consist of angiogenesis and stenosis.
A method for identifying a compound capable of modulating expression of a gene associated with an egr-1 response element consensus sequence comprising providing an expression system comprising cells or cellular extracts and an egr-1 response element operably linked to a promoter and a gene whose expression can be modulated and measured, and determining whether said compound can induce modulation of expression in said expression system.
A method for identifying a compound capable of modulating transcription arising from an egr-1 or an egr-1 consensus sequence element comprising the step of providing a test system comprising and egr-1 or an egr-1 consensus sequence element operably linked to a gene capable of expressing a detectable product, measuring a reference level of detectable product, contacting said test system with a compound to be tested and thereafter measuring the level of detectable product;
A compound capable of modulating expression of a gene associated with an egr-1 response element consensus sequence comprising a donatable nitric oxide component and a free radical scavenging anti-oxidant molecule.
Dependencies are inferred from the claim text.